"Overall, this study demonstrates the feasibility of applying QPOP as a functional combinatorial precision medicine platform to predict therapeutic sensitivities in AML and provides the basis for ...

Data elements obtained from the clinical databases for the three recent multinational openlabel clinical trials included patient age, sex, race, AML classification, the duration of first remission ...

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations ... The myeloMATCH precision medicine trials (NCT05564390 ...